Skip to content
Bored Studies
RecruitingPhase 1

Study of NTX-2001 on Alcohol Consumption in Alcohol Use Disorder

Newleos Therapeutics, Inc. · with Yale University · NCT07520292

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 21–60 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 1
Target enrollment
50
US sites recruiting
1
Study start
March 20, 2026
Record last updated
April 9, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The primary goal of this Phase 1b clinical trial is to evaluate the effects of a novel TAAR1 receptor partial agonist (NTX-2001) in adults with Alcohol Use Disorder (AUD). The main questions this trial aims to answer are:

  • Does NTX-2001 affect alcohol consumption in adults with AUD?
  • Is NTX-2001 safe and well tolerated in adults with AUD?

Researchers will compare the effects of NTX-2001 with matching placebo (look-alike capsule that contains no drug).

Participants will

  • Take NTX-2001 or matching placebo every day for 2 weeks
  • Visit the clinic 4 times over the course of 10 weeks

Being studied: NTX-2001; Placebo

Conditions: Alcohol Use Disorder

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Has provided written informed consent for the study and is willing to comply with all requirements of the protocol
  • English speaker
  • Male or female, ≥21 and ≤60 years of age.
  • Has a body mass index (BMI) 18 to 35 kg/m2 inclusive.
  • Meets DSM-5 criteria for Alcohol Use Disorder (AUD) confirmed by Mini-International Neuropsychiatric Interview (MINI).
  • If participant is of childbearing potential, must commit to practicing highly effective methods of birth control during the study and at least 14 days after the last dose.

Exclusion Criteria

  • Currently seeking alcohol treatment or have been in alcohol treatment within the past 6 months
  • Reports disliking spirits (hard liquor)
  • Current diagnosis of substance use disorder, except for tobacco use disorder or mild cannabis use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5)
  • Past or current diagnosis of schizophrenia spectrum or other psychotic disorder as defined by the DSM-5
  • Receiving psychotropics regularly, except for a stable dose of an antidepressant for at least 2 months prior to Screening
  • Is at risk for suicidal ideation as per C-SSRS
  • Has moderate or severe hepatic impairment
  • Has moderate or severe renal impairment
  • Women who are pregnant or women who are currently breastfeeding unless they plan to stop breastfeeding for the duration of the study

Recruiting US locations

  • Yale University School of Medicine, Connecticut Mental Health Center

    New Haven, CT 06519

    Site contact: Yale University School of Medicine, Connecticut Mental Health · 978-780-5937 · clinicaltrials@newleos.com

Study contacts (from the official record)

  • Newleos Therapeutics Clinical Trial Team · 978-780-5937 · clinicaltrials@newleos.com
All phase 1 studies in Connecticut →
Study of NTX-2001 on Alcohol Consumption in Alcohol Use Disorder (NCT07520292) | Bored Studies